摘要
目的:探讨阿托伐他汀与拜阿司匹林联合用药应用于预防糖尿病继发心血管疾病中的临床效果。方法:选取119例2型糖尿病患者为研究对象,采用数字表法随机分为观察组60例与对照组59例,两组患者均给予拜阿司匹林口服治疗,观察组联合阿托伐他汀口服治疗。观察两组治疗前后血脂水平、炎症因子水平、药物不良反应及继发心血管疾病的发生率。结果:血脂:观察组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)[(3.99±0.17)、(1.12±0.13)、(2.03±0.30)mmol/L]明显低于对照组,高密度脂蛋白胆固醇(HDL-C)(1.66±0.10)mmol/L明显低于对照组(P<0.05);炎症因子:观察组超敏C-反应蛋白(hs-CRP)[(6.42±2.31)mg/L]、白介素-6(IL-6)[(18.12±3.54)pg/L]明显低于对照组(P<0.05),脂联素(APN)[(11.22±4.14)μg/mL]明显高于对照组(P<0.05);继发心血管疾病:观察组继发心血管发病率(13.33%)明显低于对照组(P<0.05);不良反应:两组患者药物不良反应比较差异无统计学意义(P>0.05)。结论:阿托伐他汀联合拜阿司匹林可有效改善糖尿病患者的血脂水平,抑制炎症反应,降低心血管疾病发病率。
Objective： To study effect of aspirin combine with atorvastatin on cardiovascular disease secondary to diabetes. Methods ：A total of 119 cases patients with type 2 diabetes were divided into observation group （60 cases） and control group （59 cases）. All patients were given oral aspirin, while patients in observation group also had atorvastatin. Blood lipid levels, inflammatory factors and adverse drug reactions, incidence of cardiovascular disease secondary to diabetes were corn pared. Results：In observation groupTC, TG, LDL-C（3.99±0.17） mmol/L, （1.12±0.13） mmol/L, （2.03±0.30）mmol/ L） were significantly lower than control group. HDL-C [（18.12±3.54）pg/L] was significantly lower than control group. In observation group hs-CRP[（6.42 ±2.31 ）mg/L], IL-6 [（ 18. 12± 3.54）pg/L] were significantly lower than control group, APN[（11. 22±4.14）μg/mL] was significantly higher than that of control group. In observation group incidence of cardiovas- cular disease secondary to diabetes （13. 33~） was significantly lower than that of control group. There was no significantdifference in adverse drug reactions between two groups. Conclusion：Aspirin combine with atorvastatin can effectively improve blood lipid level, inhibit inflammatory reaction, and reduce the incidence of cardiovascular disease secondary to diabetes
出处
《海南医学院学报》
CAS
2014年第12期1652-1654,1657,共4页
Journal of Hainan Medical University
基金
湖北省高校自然科学重点研究项目(kj2010A022)~~
关键词
阿托伐他汀
拜阿司匹林
2型糖尿病
继发心血管疾病
Atorvastatin
Aspirin
Type 2 diabetes
Cardiovascular disease secondary to diabetes
